March 22, 2018
11 am to 12 pm EDT
Other than specificity, the affinity (KD) of an antibody reagent binding to a drug target is the most important property that drives PK, ADA and NAb assay performance. Kinetic properties (Kon and Koff) may be determined to calculate KD using surface-based
methods, such as Biacore or Octet. Alternatively, equilibrium-based methods may be utilized by determining concentrations of binding partners in solution. Gyrolab was evaluated as a tool to measure equilibrium solution-based KD of critical reagents
(bivalent Fabs and mouse Mab) binding to various human Mab drug targets and the data compared to kinetic-based surface methodologies, such as Octet and Biacore. Differences in affinity measurements were found across methodologies and can
be attributed to a variety of factors, including avidity, valency of interactants, assay format and matrix effects. Gyrolab is a useful tool to characterize high affinity assay reagents that are beyond the detection limits for Octet or Biacore,
and affords automation, short assay/contact time, small reagent volumes and unmodified interactants.
- Gyrolab solution-based method for measuring KD values in the low pM range
- Feasability of Gyrolab to characterize reagent affinity to Mab drug and comparison to alternate methods (Biacore and Octet)
- Case study: high affinity interaction between 2 Mabs (Low pM KD Range)
Senior Principal Scientist, Biomedicine Design, Discovery Bioanalytical and Critical Reagent Group
Alison has 25+ years experience with assay development in biotech and pharmaceutical industries, including ligand-binding assay development to support PK, immunogenicity and biomarkers, as well as extensive experience with critical reagent generation.
Alison graduated from the National University of Ireland, Maynooth, Co. Kildare, with a Bachelor of Science (Joint Honors) Degree in Biology and Physics. Her early career work was carried out in smaller biotech/research reagent companies such
as Endogen and Oncogene Research Products, where she developed commercial assays to quantitate cytokines and apoptosis markers. Alison is currently a Senior Principal Scientist and Group Lead at Pfizer, spending the past 14 years in the Biomedicine
Design group developing assays to support drug development of biotherapeutics.